R
ResMed Inc.
RMD · Healthcare
Q2 FY2026
Earning ended Dec 31, 2025Report generated Mar 10, 2026
GLP-1 Panic Repriced a Cloud Sleep Monopoly at Hardware Multiples
The market is treating GLP-1 drugs as an existential threat to ResMed's patient pool, but clinical data is inverting the thesis — GLP-1 users are starting and sustaining CPAP therapy at measurably higher rates, meaning the obesity drug wave may be expanding the diagnosed population rather than eroding it. The real ResMed story isn't the device at all — it's the compliance and billing software that now makes the company the operating system of out-of-hospital respiratory care, a recurring-revenue platform business priced as if it were pure hardware.
Flowly Score
Apr 16 Close
+54%$224.72
Fair Value
$345.00
78
Strongat $224.72
Business Strength8/10
A rare three-layer moat — hardware, compliance cloud, and billing software — that locks in patients, providers, and payers simultaneously, making displacement not just difficult but operationally irrational; the CEO/Chairman duality and founder-family dynamics introduce governance softness that prevents a 9.
Financial Resilience8/10
The Altman Z-score and Piotroski readings are near-pristine, and the dramatic FCF expansion — with CapEx running well below depreciation — confirms this is a fundamentally asset-light business underneath the medical device label; the 2022-2023 cash conversion dip was working capital congestion, not structural impairment, and the recovery validated that read entirely.
Growth & Trajectory7/10
Earnings growing materially faster than revenue is the clearest sign that the moat is maturing into a harvesting phase — operating leverage is now doing the compounding work; the SaaS segment is still early in its own growth curve and international underpenetration represents a genuine long-duration runway, but revenue growth is moderating and the baseline is already large.
Valuation8/10at $252.93
The multiple has compressed from peak panic levels to something approaching a fair exchange for business quality — the neutral DCF scenario shows meaningful upside from current prices, and the FCF yield on a business with this ROIC profile and switching cost structure is more attractive than the headline P/E implies; the market is paying hardware multiples for a business that increasingly earns software economics.
Risk6/10
Concentration risk is the clearest structural vulnerability — virtually all economic value traces back to sleep-disordered breathing, so a structural shock to CPAP adoption doesn't clip the growth rate, it amputates the business; the GLP-1 bear case is weakening on the clinical evidence but isn't closed, and CMS reimbursement compression on durable medical equipment remains a sword the company cannot dodge by being innovative.
The investment case hinges on a mispricing created by a fear that hasn't materialized. The market spent two years discounting ResMed as a GLP-1 casualty while the actual business quietly accelerated — FCF expanded dramatically, ROIC recovered to above-cost-of-capital levels, margins are inflecting higher, and the SaaS segment is proving its operating leverage thesis. You're buying a near-monopoly with multi-layer switching costs, growing recurring revenues, and a proprietary dataset that compounds in value annually, at a multiple that implies the worst of the bear case rather than the most likely outcome. The direction of travel is toward a higher-quality business than the one that existed five years ago. Each passing year deepens the AirView data moat, adds another HME or senior care facility to Brightree or MatrixCare, and advances the company's positioning as an indispensable platform rather than a manufacturer. The 60,000 CME completions targeting primary care physicians — with three-quarters reporting intent to change screening practices — is a demand generation flywheel that will take years to fully show up in device volumes. International underpenetration in markets where sleep apnea awareness is still nascent represents a second growth curve that the current valuation treats as nearly worthless. The single most concrete risk is CMS reimbursement compression on durable medical equipment. This is not a hypothetical — it has happened before and structurally it flows through the HME dealer channel that distributes ResMed's products, meaning the company's technology leadership provides zero protection. A meaningful DME rate cut would impair dealer economics, slow prescribing velocity, and suppress device volumes regardless of how good AirSense devices are. Unlike the GLP-1 risk, which is weakening on the clinical evidence, CMS reimbursement risk is a pure policy variable that no amount of innovation or moat durability can neutralize.